Bristol-Myers Squibb is buying Celgene in a $74 billion deal
Jan 3, 2019, 18:01 IST
Advertisement
- Bristol-Myers Squibb has agreed to acquire Celgene, the drugmakers announced Thursday in a deal valued at $74 billion.
- The deal will pay Celgene shareholders 1 Bristol-Myers Squibb share and $50 cash for each Celgene share they own.
- The deal combines a massive pharmaceutical company with a biotech giant, both of which have a big presence in cancer drug development.
- Watch Celgene and BMS trade in real time.